Fludarabine and Cyclophosphamide Using An Attenuated Dose Schedule Is a Highly Effective Regimen for Patients with Indolent Lymphoid Malignancies

Abstract

BACKGROUND. Preclinical data have supported the use of fludarabine and cyclophosphamide (FC) in combination for the treatment of indolent lymphoid malignancies. Previously reported schedules were highly effective, but were complicated by significant myelotoxicity and infectious complications. In the current study, the authors analyzed their experience with an attenuated dose regimen to determine whether equivalent efficacy could be achieved with reduced toxicity. METHODS. Sixty-four patients with indolent lymphoid malignancies were treated with intravenous fludarabine at a dose of 25 mg/m2 and cyclophosphamide at a dose of 250 mg/m2, each given on Days 1-3 for a median of 4 cycles. The media..